Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00557518




Registration number
NCT00557518
Ethics application status
Date submitted
12/11/2007
Date registered
14/11/2007
Date last updated
30/01/2009

Titles & IDs
Public title
Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
Scientific title
A Randomized, Placebo-Controlled Trial of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
Secondary ID [1] 0 0
ALT-711-0424
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 1 0 0
Diabetic Nephropathy 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes
Renal and Urogenital 0 0 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Alagebrium
Treatment: Drugs - Placebo

Active Comparator: 1 -

Placebo Comparator: 2 -


Treatment: Drugs: Alagebrium
200 mg bid

Treatment: Drugs: Placebo
bid
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in albumin excretion rate (µg/min)
Timepoint [1] 0 0
24 weeks
Secondary outcome [1] 0 0
Albumin:creatinine ratio(mg/g), plasma renin level, collagen markers, AGE related markers, 24 hour blood pressure determinations
Timepoint [1] 0 0
24 weeks

Eligibility
Key inclusion criteria
- Insulin-dependent type 1 diabetes

- Age 18-65 years

- Diagnosis of established microalbuminuria

- Blood pressure <140 mm Hg, diastolic blood pressure <90 mm Hg

- HbA1c <10%
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Body mass index >40 kg/m2

- Cardiovascular event within 6 months prior to screening

- History of acute myocardial infarction within 12 months prior to screening

- Serum creatinine >1.5 mg/dL

- Receiving chronic nonsteroidal anti-inflammatory therapy

- Receiving antihypertensive therapy except for angiotensin converting enzyme inhibitors
or angiotensin receptor blockers

- Any significant systemic illnesses,medical conditions or abnormal laboratory values

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/11/2009
Actual
Sample size
Target
80
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
International Diabetes Institute - Caulfield
Recruitment hospital [3] 0 0
Dept. of Clinical and Biomedical Science Myers House - Geelong
Recruitment hospital [4] 0 0
Austin Health - Heidelburg
Recruitment hospital [5] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3162 - Caulfield
Recruitment postcode(s) [3] 0 0
3220 - Geelong
Recruitment postcode(s) [4] 0 0
3084 - Heidelburg
Recruitment postcode(s) [5] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
Denmark
State/province [1] 0 0
Gentofte

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Synvista Therapeutics, Inc
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Juvenile Diabetes Research Foundation
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Based upon the preclinical evidence in models of diabetic nephropathy under conditions
approximating both type I and II diabetes, treatment with alagebrium appears to have
favorable and advantageous effects on the biochemical, structural, pathological and
functional hallmarks of diabetic nephropathy. The renoprotective effects of alagebrium in
preclinical models favor the evaluation of this drug in patients with type I diabetes.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00557518
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mark E Cooper, MBBS, PhD
Address 0 0
Baker Heart Research Institute, Melbourne, Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00557518